These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. Wilkoff BL; Hess M; Young J; Abraham WT J Cardiovasc Electrophysiol; 2004 Sep; 15(9):1002-9. PubMed ID: 15363071 [TBL] [Abstract][Full Text] [Related]
25. Arrhythmia rate distribution and tachyarrhythmia therapy in an ICD population: results from the INTRINSIC RV trial. Sullivan RM; Russo AM; Berg KC; Stolen KQ; Seth M; Perschbacher D; Day JD; Olshansky B Heart Rhythm; 2012 Mar; 9(3):351-8. PubMed ID: 22016074 [TBL] [Abstract][Full Text] [Related]
26. Importance of abortive shock capability with electrogram storage in cardioverter-defibrillator devices. Hurwitz JL; Hook BG; Flores BT; Marchlinski FE J Am Coll Cardiol; 1993 Mar; 21(4):895-900. PubMed ID: 8450157 [TBL] [Abstract][Full Text] [Related]
27. Dual chamber implantable cardioverter defibrillator benefits and limitations. Fan K; Lee K; Lau CP J Interv Card Electrophysiol; 1999 Oct; 3(3):239-45. PubMed ID: 10490480 [TBL] [Abstract][Full Text] [Related]
28. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations). Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697 [TBL] [Abstract][Full Text] [Related]
30. Implantable Cardioverter Defibrillator Programming Characteristics, Shocked Rhythms, and Survival Among Patients Under Thirty Years of Age. Chang PM; Powell BD; Jones PW; Carter N; Hayes DL; Saxon LA J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1183-1190. PubMed ID: 27334356 [TBL] [Abstract][Full Text] [Related]
31. New ICD-technologies: first clinical experience with dual-chamber sensing for differentiation of supraventricular tachyarrhythmias. Osswald S; Cron TA; Sterns L; Alt E; Stotts L; Coenen M Pacing Clin Electrophysiol; 1998 Jan; 21(1 Pt 2):292-5. PubMed ID: 9474691 [TBL] [Abstract][Full Text] [Related]
32. Supraventricular arrhythmias in children and young adults with implantable cardioverter defibrillators. Love BA; Barrett KS; Alexander ME; Bevilacqua LM; Epstein MR; Triedman JK; Walsh EP; Berul CI J Cardiovasc Electrophysiol; 2001 Oct; 12(10):1097-101. PubMed ID: 11699514 [TBL] [Abstract][Full Text] [Related]
33. Enhanced detection criteria in implantable cardioverter-defibrillators to avoid inappropriate therapy. Schaumann A; von zur Mühlen F; Gonska BD; Kreuzer H Am J Cardiol; 1996 Sep; 78(5A):42-50. PubMed ID: 8820835 [TBL] [Abstract][Full Text] [Related]
34. Sex Differences in Inappropriate ICD Device Therapies: MADIT-II and MADIT-CRT. Tompkins CM; McNitt S; Polonsky B; Daubert JP; Wang PJ; Moss AJ; Zareba W; Kutyifa V J Cardiovasc Electrophysiol; 2017 Jan; 28(1):94-102. PubMed ID: 27696593 [TBL] [Abstract][Full Text] [Related]
35. Clinical experience with a new detection algorithm for differentiation of supraventricular from ventricular tachycardia in a dual-chamber defibrillator. Sinha AM; Stellbrink C; Schuchert A; Mox B; Jordaens L; Lamaison D; Gill J; Kaplan A; Merkely B; J Cardiovasc Electrophysiol; 2004 Jun; 15(6):646-52. PubMed ID: 15175058 [TBL] [Abstract][Full Text] [Related]
36. [Inadequate therapies with implantable cardioverter-defibrillators--incidence, etiology, predictive factors and preventive strategies]. Weber M; Block M; Brunn J; Bänsch D; Böcker D; Hammel D; Gietzen F; Breithardt G Z Kardiol; 1996 Nov; 85(11):809-19. PubMed ID: 9064943 [TBL] [Abstract][Full Text] [Related]
37. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Sweeney MO; Wathen MS; Volosin K; Abdalla I; DeGroot PJ; Otterness MF; Stark AJ Circulation; 2005 Jun; 111(22):2898-905. PubMed ID: 15927965 [TBL] [Abstract][Full Text] [Related]
38. Causes and clinical consequences of inappropriate shocks experienced by patients wearing a cardioverter-defibrillator. Berger JM; Sengupta JD; Bank AJ; Casey SA; Witt D; Sharkey SW; Stanberry LI; Hauser RG Heart Rhythm; 2023 Jul; 20(7):970-975. PubMed ID: 37211148 [TBL] [Abstract][Full Text] [Related]
39. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. Daubert JP; Zareba W; Hall WJ; Schuger C; Corsello A; Leon AR; Andrews ML; McNitt S; Huang DT; Moss AJ; J Am Coll Cardiol; 2006 Jan; 47(1):98-107. PubMed ID: 16386671 [TBL] [Abstract][Full Text] [Related]